Manidipine: a Review of Its Use in the Management of Hypertension

Overview

Journal Drugs

Specialty Pharmacology

Date 2004 Aug 27

PMID 15329044

Citations 13

Authors

Kate McKeage

Lesley J Scott

Affiliations

Soon will be listed here.

Abstract

Manidipine is a lipophilic, third-generation dihydropyridine calcium channel antagonist with a high degree of selectivity for the vasculature, thereby inducing marked peripheral vasodilation with negligible cardiodepression. In addition, manidipine does not significantly affect norepinephrine levels, suggesting a lack of sympathetic activation. It has a gradual onset of action and a long duration of action enabling once daily administration. Furthermore, manidipine dilates both the efferent and the afferent renal arterioles and appears to have beneficial renal effects unrelated to its antihypertensive effect. Once-daily oral manidipine is an effective and generally well tolerated antihypertensive agent for younger and elderly adult patients with mild-to-moderate hypertension. In particular, in a large double-blind trial, the incidence of ankle oedema was significantly lower in manidipine than in amlodipine recipients. Manidipine is also effective in hypertensive patients with comorbidities, such as type 2 diabetes mellitus and/or renal impairment, and appears to improve insulin sensitivity without affecting metabolic function. Thus, manidipine represents a first-line treatment option for patients with essential mild-to-moderate hypertension.

Citing Articles

Host cell transcriptomic response to the multidrug-resistant clonal outbreak Beijing strain reveals its pathogenic features.

Prombutara P, Siregar T, Laopanupong T, Kanjanasirirat P, Khumpanied T, Borwornpinyo S Virulence. 2022; 13(1):1810-1826.

PMID: 36242542 PMC: 9578452. DOI: 10.1080/21505594.2022.2135268.

The Challenge and Importance of Integrating Drug-Nutrient-Genome Interactions in Personalized Cardiovascular Healthcare.

Stouras I, Papaioannou T, Tsioufis K, Eliopoulos A, Sanoudou D J Pers Med. 2022; 12(4).

PMID: 35455629 PMC: 9033008. DOI: 10.3390/jpm12040513.

Transcriptional response to the host cell environment of a multidrug-resistant Mycobacterium tuberculosis clonal outbreak Beijing strain reveals its pathogenic features.

Aiewsakun P, Prombutara P, Siregar T, Laopanupong T, Kanjanasirirat P, Khumpanied T Sci Rep. 2021; 11(1):3199.

PMID: 33542438 PMC: 7862621. DOI: 10.1038/s41598-021-82905-x.

Calcium Channel Blocker-Associated Chyloperitoneum in Patients Receiving Peritoneal Dialysis: A Systematic Review.

Kim S, Yu Y, Kwon J, Yoo H, Jung S, Lee E Int J Environ Res Public Health. 2019; 16(8).

PMID: 31013922 PMC: 6517940. DOI: 10.3390/ijerph16081333.

How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension.

Tocci G, Desideri G, Roca E, Calcullo C, Crippa M, De Luca N High Blood Press Cardiovasc Prev. 2017; 25(1):25-34.

PMID: 29197935 PMC: 5842506. DOI: 10.1007/s40292-017-0242-z.

References

Zanchetti A, Omboni S, La Commare P, De Cesaris R, Palatini P . Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. J Cardiovasc Pharmacol. 2001; 38(4):642-50. DOI: 10.1097/00005344-200110000-00017. View

Saku K, Zhang B, Hirata K, Liu R, Sasaki N, Sakai T . Effects of manidipine and delapril on serum lipids, lipoproteins, and apolipoproteins in patients with mild to moderate essential hypertension: a randomized trial with one-year follow-up. Clin Ther. 1992; 14(6):813-20. View

Fujimaki M, Nagase M, Uchida S . Long-term effect of manidipine on renal function and structure in uninephrectomized spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1997; 24(7):506-12. DOI: 10.1111/j.1440-1681.1997.tb01236.x. View

Ogihara T, Nakagawa M, Ishikawa H, Mikami H, Takeda K, Nonaka H . Effect of manidipine, a novel calcium channel blocker, on quality of life in hypertensive patients. Blood Press Suppl. 1992; 3:135-9. View

Iimura O, Shimamoto K, Masuda A, Higashiura K, Miyazaki Y, Hirata A . Effects of a calcium channel blocker, manidipine, on insulin sensitivity in essential hypertensives. J Diabetes Complications. 1995; 9(4):215-9. DOI: 10.1016/1056-8727(95)80005-y. View

Shiba T, Inoue M, Tada H, Hayashi Y, Okuda Y, Fujita R . Delapril versus manidipine in hypertensive therapy to halt the type-2-diabetes-mellitus-associated nephropathy. Diabetes Res Clin Pract. 2000; 47(2):97-104. DOI: 10.1016/s0168-8227(99)00114-x. View

Ram C . Usefulness of lercanidipine, a new calcium antagonist, for systemic hypertension. Am J Cardiol. 2002; 89(2):214-5. DOI: 10.1016/s0002-9149(01)02203-2. View

Rosillon D, Stockis A, Poli G, Acerbi D, Lins R, Jeanbaptiste B . Food effect on the oral bioavailability of Manidipine: single dose, randomized, crossover study in healthy male subjects. Eur J Drug Metab Pharmacokinet. 1998; 23(2):197-202. DOI: 10.1007/BF03189339. View

Fogari R, Zoppi A, Corradi L, Preti P, Malalamani G, Mugellini A . Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. J Hypertens. 2001; 18(12):1871-5. DOI: 10.1097/00004872-200018120-00023. View

10.

Kobayashi S, Hishida A . Effects of a calcium antagonist, manidipine, on progressive renal injury associated with mild hypertension in remnant kidneys. J Lab Clin Med. 1995; 125(5):572-80. View

11.

Saruta T, Suzuki H . Efficacy of manidipine in the treatment of hypertension with renal impairment: a multicenter trial. Am Heart J. 1993; 125(2 Pt 2):630-4. DOI: 10.1016/0002-8703(93)90214-t. View

12.

Reams G, Villarreal D, Wu Z, Wang X, Luger A, Bauer J . An evaluation of the renal protective effect of manidipine in the uninephrectomized spontaneously hypertensive rat. Am Heart J. 1993; 125(2 Pt 2):620-5. DOI: 10.1016/0002-8703(93)90212-r. View

13.

Shimizu M, Ogawa K, Sasaki H, Uehara Y, Otsuka Y, Okumura H . Effects of efonidipine, an L- and T-Type dual calcium channel blocker, on heart rate and blood pressure in patients with mild to severe hypertension: an uncontrolled, open-label pilot study. Curr Ther Res Clin Exp. 2014; 64(9):707-14. PMC: 4053062. DOI: 10.1016/j.curtheres.2003.11.004. View

14.

Fogari R, Zoppi A, Lusardi P, Preti P, Poletti L, Mugellini A . Evaluation by 24-hour ambulatory blood pressure monitoring of efficacy of manidipine hydrochloride 10, 20 or 40 mg once daily as compared to placebo in treating mild to moderate essential hypertension: a double-blind, randomized, parallel group,.... Blood Press Suppl. 1996; 5:16-23. View

15.

. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003; 21(6):1011-53. DOI: 10.1097/00004872-200306000-00001. View

16.

Bellinghieri G, Mazzaglia G, Savica V, Santoro D . Effects of manidipine and nifedipine on blood pressure and renal function in patients with chronic renal failure: a multicenter randomized controlled trial. Ren Fail. 2003; 25(5):681-9. DOI: 10.1081/jdi-120024284. View

17.

Cheer S, McClellan K . Manidipine: a review of its use in hypertension. Drugs. 2001; 61(12):1777-99. DOI: 10.2165/00003495-200161120-00010. View

18.

Atarashi K, Takagi M, Minami M, Kimura Y, Matsuoka H, Sugimoto T . Effects of manidipine and delapril on glucose and lipid metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus. Blood Press Suppl. 1992; 3:130-4. View

19.

Celentano A, Crivaro M, Perticone F, Palmieri V, Oliviero M, Tammaro P . Anti-hypertensive effect of manidipine: 24 hours monitoring evaluation and Doppler-echocardiographic remarks. Blood Press Suppl. 1996; 5:29-35. View

20.

Mancia G, Omboni S, Agabiti-Rosei E, Casati R, Fogari R, Leonetti G . Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients. J Cardiovasc Pharmacol. 2000; 35(6):926-31. DOI: 10.1097/00005344-200006000-00015. View